Maurizio Oliveri

Trading enthusiast • AI systems developer

[Maurizio Oliveri @moliveri70]

Raphael Pharmaceutical Inc. $RAPH reports dual leadership transitions: Chairman Dhadha departing June 30 and CFO/General Counsel Ofir departing July 16. Both cited no disagreement with the company. #biotech

[Maurizio Oliveri @moliveri70]

$VIVS priced public offering of 4.7M shares at $0.85, representing ~12% discount to MA20. Equal warrant coverage; existing warrants repriced to $0.85. Offering nearly doubles float. #biotech

[Maurizio Oliveri @moliveri70]

$KLRS Kalaris announces expanded Phase 1 cohort (N=20) reinforcing pharmacokinetics, BCVA and durability signals. No new intraocular inflammation observed at 2.5mg post-manufacturing optimization. Phase 1b/2 MAD readout expected 1H2027. ...

[Maurizio Oliveri @moliveri70]

Four Leaf Acquisition Corp ($FOURQ) terminates merger agreement with its sole target after approximately seven months. The SPAC faces uncertainty following four director resignations within five weeks, with no identified acquisition pros...

[Maurizio Oliveri @moliveri70]

$XOMA files holdings update confirming July 13, 2026 CVR record date per merger agreement. CVRs tied to $39.00 cash component. #biotech

[Maurizio Oliveri @moliveri70]

VPR Brands ($VPRB) received $14.9M from patent license settlement with RJ Reynolds Vapor. Material cash inflow reflects IP monetization. #biotech

[Maurizio Oliveri @moliveri70]

Inhibrx Biosciences secured $100M in Term C financing with potential for $225M more, providing non-dilutive capital to advance ozekibart and INBRX-106 through key data milestones. $INBX #biotech

[Maurizio Oliveri @moliveri70]

Intuitive Surgical reports broad-based beat across procedures, placements, and margins. da Vinci 5 ramp and Ion acceleration both demonstrate strong momentum in Q3 results. $ISRG #biotech

[Maurizio Oliveri @moliveri70]

@LogicalThesis You’re in good company man 😅

[Maurizio Oliveri @moliveri70]

Gain Therapeutics ($GANX) files disclosure confirming operational continuity and Phase 2 timeline. No new clinical data included in filing. #biotech

[Maurizio Oliveri @moliveri70]

$FRMM closed $12M acquisition of CFM56-7B engine, now revenue-generating under active lease. Fifth engine expected imminently. Real-world asset tokenization strategy in early stages. #biotech

[Maurizio Oliveri @moliveri70]

Edgewise Therapeutics $EWTX files amended 8-K reflecting $1.55B cash receipt from completed transaction (closed July 10). Pro forma balance sheet shows ~$2B+ in assets post-deal. #biotech

[Maurizio Oliveri @moliveri70]

TOMI Environmental Solutions ($TOMZ) announced a reverse stock split as it addresses share price levels. The action typically reflects compliance considerations rather than operational developments. #biotech

[Maurizio Oliveri @moliveri70]

SharonAI Holdings Inc. $SHAZ announced a large partnership contract expanding contracted capacity to 116MW of 132MW total. Revenue recognition deferred to 2027. Counterparty details remain undisclosed. #biotech

[Maurizio Oliveri @moliveri70]

$HRMY reports record quarterly revenue and reiterates full-year guidance. CFO departure noted. Company demonstrates strong commercial execution in rare disease market. #biotech

[Maurizio Oliveri @moliveri70]

Cardiff Oncology prices $9.75M public offering at $1.05/share, adding ~9.3M shares plus warrants. Insider participation noted at $1.435. No near-term clinical catalysts disclosed. $CRDF #biotech

[Maurizio Oliveri @moliveri70]

Arbutus Biopharma reports $178M cash position and announces $230M shareholder return program alongside international IP enforcement actions against Pfizer/BioNTech. $ABUS #biotech

[Maurizio Oliveri @moliveri70]

$ATAI to merge with Beckley in definitive agreement at $6.75/share cash plus contingent value rights up to $2.50 tied to BPL-003/VLS-01 clinical milestones. Deal values equity at ~$2.8B. #biotech

[Maurizio Oliveri @moliveri70]

INSM reports positive open-label extension data for TPIP in pulmonary arterial hypertension, showing 6-minute walk distance improvement of 55m and NT-proBNP reduction of 60%. Phase 3 PALM-PAH trial remains pivotal. #biotech $INSM

[Maurizio Oliveri @moliveri70]

$UNH reports strong Q2 results with $112B in revenues and 86.7% MCR. Adjusted EPS of $6.38 with raised FY guidance. Optum achieved 160bps margin expansion. #biotech